Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: Sam Lee who wrote (116)	7/22/1998 9:29:00 AM
From: Stemwriter	Read Replies (1) \| Respond to of 320

See the Yahoo board for the results of the conference call yesterday. The bottom line is as Sam said - no deal yet but all the programs seem to be going well. My source inside the company said about the same thing - they don't know why the stock dropped, maybe because little happened in June after expectations were raised. He feels that Nyotran seems to have a broader spectrum of action than the competition (amphotericin and itraconazole). Still, as a new investor in the company I wonder. What is the potential market for such an agent? Why are they having so much trouble completing a deal? And why is the market reacting so negatively to them? I guess we'll see in the next day or so what the market reaction to the conference call was.